Gossamer Bio announces up to $250 million private placement
Gossamer Bio says it has entered a structured private placement for up to $250 million, including $150 million of committed capital, to fund seralutinib through potential FDA approval.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.